



# 6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

[sciforum.net/conference/ECMC2020](http://sciforum.net/conference/ECMC2020)

sponsored by



## Development of water-soluble ternary system for enhancing biological activities of mefenamic acid

**Dounia Sid<sup>1,2</sup>, Milad Baitiche<sup>1,\*</sup>, Zineb Elbahri<sup>3</sup>, Ferhat Djerboua<sup>1</sup>, Mokhtar Boutahala<sup>4</sup> and Marc Le Borgne<sup>2,5,\*</sup>**

<sup>1</sup>Laboratoire de Préparation, Modification et Applications des Matériaux Polymériques Multiphasiques, Département de Génie des Procédés, Faculté de Technologie, Université Ferhat Abbas Sétif-1, Boulevard du Sipion, Sétif 19000, Algérie; <sup>2</sup> EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, Université Claude Bernard Lyon 1, Univ Lyon, Lyon, 69373, France; <sup>3</sup> Laboratory of Materials and Catalysis, Faculty of Exact Sciences, Djillali Liabès University of Sidi Bel Abbès, 22000 Algeria; <sup>4</sup> Laboratoire de Génie des Procédés Chimiques, Département de Génie des Procédés, Faculté de Technologie, Université Ferhat Abbas Sétif-1, Boulevard du Sipion, Sétif 19000, Algérie; <sup>5</sup>Small Molecules for Biological Targets Team, Centre de recherche en cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ Lyon, Lyon, 69373, France




Université Claude Bernard  Lyon 1

\* Corresponding authors: [baitiche\\_milad@yahoo.fr](mailto:baitiche_milad@yahoo.fr); [marc.le-borgne@univ-lyon1.fr](mailto:marc.le-borgne@univ-lyon1.fr)

# Development of water-soluble ternary system for enhancing biological activities of mefenamic acid

## Graphical Abstract



## Abstract:

The aim of this work is to investigate the solubility enhancement of mefenamic acid (MA), a non-steroidal anti-inflammatory agent, by formation of stable amorphous ternary system (MA, polyvinylpyrrolidone (PVP),  $\beta$ -cyclodextrin ( $\beta$ -CD)) compared to the binary system (MA,  $\beta$ -CD). Firstly, on the basis of the molecular docking simulation and job's plot results, three methods were adopted for the preparation of the binary inclusion complexes at the ratio of 2:1 of MA: $\beta$ -CD, namely solvent co-evaporation (CE), kneading (KN) and physical mixture (PM). However, in order to decrease tendency to self-assembly of cyclodextrins and form aggregates in aqueous media, each binary system was co-milled at ambient temperature in presence of different ratios of a highly water-soluble polymer (PVP). These complexes were characterized using Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), nuclear magnetic resonance ( $^1\text{H}$ - and  $^{13}\text{C}$ -NMR) spectroscopy and scanning electron microscopy (SEM) techniques. The release of the drug from the diverse formulations was also investigated by means of UV-VIS spectroscopy. Finally anti-inflammatory and anti-nociceptive activities were performed. The results showed that the solubility of MA in water from ternary complexes was significantly improved.

**Keywords:** Mefenamic acid;  $\beta$ -cyclodextrin; polyvinylpyrrolidone; solubility; *in vivo*.



## Introduction



- ✓ **Physicochemical properties** and **ADME** (Absorption, Distribution, Metabolism, Elimination) **parameters** of a drug substance are essential to ensure the accessibility to its target(s).
- ✓ Only the **free part of the drug substance** diffuses in tissues from the blood and then can access to the active binding site of the desired target.
- ✓ Among all parameters to control for a successful treatment, an **acceptable level of drug substance solubility** is required.
- ✓ In the case of low solubility drug substances, **inclusion complexes** with  $\beta$ -CD can be an interesting alternative to facilitate drug administration.
- ✓ **To increase complexation and to optimize solubilization**, addition of small quantities of a suitable hydrophilic polymer to a drug: $\beta$ -CD system is very favorable.



# Introduction


## ✓ Mefenamic acid (MA) and its physicochemistry

- ✓ 2-[(2,3-dimethylphenyl)amino]benzoic acid.
- ✓ A potent non-steroidal anti-inflammatory drug (NSAID).




## Results and discussion – *Determination of complex stoichiometry*

Phase solubility diagram



✓  $\beta$ -CD formed  $A_N$ -subtype complexes with MA. This fact implies that  $\beta$ -CD is proportionally less effective at higher concentrations.

Continuous variation plot (Job's plot)



✓ The maximum  $\Delta_{Abs}$  variation was observed at mole fraction value of 0.67. This suggests a 2:1 stoichiometric ratio of MA: $\beta$ -CD.



## Results and discussion – *In silico* molecular modeling studies


| $\Delta G$ values in Kcal.mol <sup>-1</sup> |                   |                  |                            |                        |                             |                 |
|---|-------------------|------------------|----------------------------|------------------------|-----------------------------|-----------------|
| Ratio<br>(MA: $\beta$ -<br>CD)              | Bind <sup>a</sup> | Docking<br>score | Glide<br>Lipo <sup>b</sup> | Glide vdw <sup>c</sup> | Glide<br>Hbond <sup>d</sup> | Glide<br>Emodel |
| 1:1 (IC2)                                   | -21.468           | -4.575           | -2.179                     | -21.123                | -0.042                      | -26.612         |
| 2:1 (IC1)                                   | -37.698           | -7.890           | -3.454                     | -37.387                | -0.202                      | -46.262         |
| 1:2 (IC3)                                   | -35.995           | -7.375           | -3.139                     | -28.990                | -0.160                      | -50.976         |

<sup>a</sup> free energy of binding (Glide energy); <sup>b</sup> free energy of binding from lipophilic binding; <sup>c</sup> free energy of binding from van der Waals energy; <sup>d</sup> free energy of binding from hydrogen bonding.





✓ **IC1** - (2:1) MA: $\beta$ -CD - is the most stable complex (highest docking score and glide energy).

✓ **Contribution of Van der Waals** is the most important.

✓ **Introduction of a second MA molecule** in the primary complex enhances the stability (further hydrogen electrostatic interaction and improved filling of the  $\beta$ -CD cavity)



## Results and discussion – *In silico* molecular modeling studies

|  |   |   |
|--|---|---|
|   |    |   |
| <b>MA</b><br>Phobic: 5.28 CÅ<br>Phillic: 234.95 CÅ   | <b>β-CD</b><br>Phobic: 264.75 CÅ<br>Phillic: 348.44 CÅ  | <b>2 β-CD</b><br>Phobic: 371.46 CÅ<br>Phillic: 610.83 CÅ  |
|                                        |   |                                        |
| <b>IC1</b><br>Phobic: 89.80 CÅ<br>Phillic: 692.85 CÅ<br>Dielectric (solvation) energy:<br>-118.67 Kcal.mol <sup>-1</sup> | <b>IC2</b><br>Phobic: 137.09 CÅ<br>Phillic: 525.07 CÅ<br>Dielectric (solvation) energy:<br>-115.89 Kcal.mol <sup>-1</sup> | <b>IC3</b><br>Phobic: 552.53 CÅ<br>Phillic: 727.03 CÅ<br>Dielectric (solvation) energy:<br>-162.72 Kcal.mol <sup>-1</sup> |

✓ **Hydrophobic** (brown) and **hydrophilic** (blue) **surface areas** of MA, β-CD and MA:β-CD binary inclusion complexes (CÅ, cubic Ångströms).

✓ **Hydrophilic area** increases upon formation of IC1 ((2:1) MA:β-CD).

✓ **Higher polar surface area** of the supramolecular inclusion complex improved the MA solubility.



## Results and discussion – *Preparation of solid complexes and loading*

✓ According to job's plot results and the molecular docking observations, **(2:1) MA:β-CD complexes** were prepared by three methods

Physical mixture (PM)

Kneading (KN)

Co-evaporation (CE)

| Complex                          | CE           |
|----------------------------------|--------------|
| Experimental yield (%)           | 90.1         |
| Drug content (%)                 | 28.96 ± 0.39 |
| Experimental molar ratio MA:β-CD | 1.9:1        |


✓ With an experimental loading value of 28.96%, the ratio of (2:1) MA:β-CD complex was also confirmed.



## Results and discussion – *Characterization of the ingredients and their complexes*

### FTIR


- ✓ The presence of chemical incompatibility among pure MA and  $\beta$ -CD is ruled out.
- ✓ A good indication of the inclusion complex formation in the FTIR spectra for the KN and CE complexes.
- ✓ No new chemical bonds are formed with the obtained complexes.



## Results and discussion – *Characterization of the ingredients and their complexes*

### PXRD


- ✓ The **same diffraction peaks** of MA and  $\beta$ -CD clearly appear **in PM**, which indicates the absence of interaction between them.
- ✓ **Loss of the crystalline nature of MA** in the KN and CE complexes suggests partial inclusion of MA in the  $\beta$ -CD cavity.



# Results and discussion – *Characterization of the ingredients and their complexes*

## DSC


- ✓ The **presence of the endothermic peaks** of the two individual components at their corresponding temperatures indicates the absence of chemical interaction between them.
- ✓ The **thermogram of binary inclusion complexes** illustrates the characteristic endothermic peak of the drug with reduced sharpness and intensity as compared to the pure drug, indicating an incomplete inclusion of the drug in the  $\beta$ -CD cavity.



# Results and discussion – *Characterization of the ingredients and their complexes*

## <sup>1</sup>H NMR

| MA Protons | $\delta_{\text{guest}}$ | CIS (CE) | CIS (KN) | CIS (PM) |
|------------|-------------------------|----------|----------|----------|
| H-1        | 12.98                   | -2.23    | -        | 0        |
| H-2        | 9.45                    | 1.30     | 0.72     | 0        |
| H-3        | 7.89                    | 0        | 0        | 0        |
| H-4        | 7.31                    | -0.18    | -0.09    | 0        |
| H-5        | 7.12                    | -0.10    | 0.01     | 0        |
| H-6        | 7.03                    | -0.21    | 0.05     | 0        |
| H-7        | 6.72                    | -0.09    | -0.05    | 0        |
| H-8        | 6.70                    | -0.09    | -0.05    | 0        |
| H-9        | 6.68                    | -0.08    | -0.05    | 0        |
| H-10       | 2.29                    | -0.03    | -0.01    | 0        |
| H-11       | 2.10                    | 0.01     | 0.01     | 0        |




- ✓ <sup>1</sup>H NMR Chemical shifts for CH protons of MA alone ( $\delta_{\text{guest}}$ ) and their complexation induced shifts (CIS =  $\delta_{\text{complex}} - \delta_{\text{guest}}$ ) in DMSO-*d*<sub>6</sub> at 25 °C.
- ✓ The OH and NH functions of guest participate in the formation of the inclusion complex leading to a more stable complex (CE).



# Results and discussion – *Characterization of the ingredients and their complexes*

<sup>13</sup>C NMR






| MA Carbons | $\delta_{\text{guest}}$ | CIS (CE) | CIS (KN) | CIS (PM) |
|------------|-------------------------|----------|----------|----------|
| C-1        | 170.66                  | -        | 0.34     | 0        |
| C-2        | 149.22                  | -2.2     | -1.43    | -0.02    |
| C-3        | 138.81                  | 1.4      | 0.57     | 0        |
| C-4        | 138.35                  | -0.93    | -0.72    | 0        |
| C-5        | 134.66                  | -2.76    | -2.22    | 0        |
| C-6        | 132.17                  | -1.16    | -0.35    | 0        |
| C-7        | 131.71                  | -2.64    | -1.68    | -0.02    |
| C-8        | 129.89                  | -1.26    | -1.08    | -0.01    |
| C-9        | 126.49                  | -2.22    | -1.28    | 0.01     |
| C-10       | 122.66                  | -        | -2.31    | -0.02    |
| C-11       | 116.71                  | 2.16     | -0.6     | 0.01     |
| C-12       | 113.55                  | 2.43     | -0.62    | -0.01    |
| C-13       | 111.69                  | 1.11     | -        | -0.03    |
| C-14       | 14.14                   | -0.45    | -0.45    | 0        |
| C-15       | 20.69                   | -0.31    | -0.38    | 0.01     |



- ✓ <sup>13</sup>C NMR Chemical shifts for carbons of MA alone ( $\delta_{\text{guest}}$ ) and their complexation induced shifts ( $\text{CIS} = \delta_{\text{complex}} - \delta_{\text{guest}}$ ) in DMSO-*d*<sub>6</sub> at 25 °C.
- ✓ All the carbon atoms of MA show an upshift, the maximum corresponds to C1 of guest which confirms that C=O is involved in the interaction.
- ✓ By CE method, the most stable complex is obtained.




# Results and discussion – *Characterization of the ingredients and their complexes*



- ✓ **MA crystals** are adhered to smooth surface of  $\beta$ -CD (**in PM**).
- ✓ **In KN complex**, a reduction in the agglomerated drug on the surface of  $\beta$ -CD is observed.
- ✓ **In CE complex**, the crystal nature of MA disappeared. Micrographs show small, more agglomerated, and amorphous smooth structures, which suggest that MA is well dispersed in the  $\beta$ -CD cavities.



## Results and discussion – *In vitro* drug release test



- ✓ The improved MA dissolution characteristics of the PM complex may be explained by the drug wettability enhancement.
- ✓ The greater enhancement of MA dissolution in KN and CE complexes is due to partial trapping of the drug in  $\beta$ -CD verified by molecular modeling, FTIR, DSC, XRPD and SEM.




## Results and discussion – *Mathematical models of drug release kinetics*

| MA:β-CD | First order    |                                     | Higuchi        |  |         | Kosmeyer-Peppas |                 |        |
|---------|----------------|-------------------------------------|----------------|--|---------|-----------------|-----------------|--------|
|         | R <sup>2</sup> | K <sub>1</sub> (min <sup>-1</sup> ) | R <sup>2</sup> | K <sub>H</sub> x100 (min <sup>-1/2</sup> ) | a       | R <sup>2</sup>  | K <sub>KP</sub> | n      |
| PM      | 0.6553         | 0.0022                              | 0.8363         | 1.2367                                     | 31.7150 | 0.9424          | 3.5851          | 0.0997 |
| KN      | 0.9113         | 0.0054                              | 0.9934         | 4.6504                                     | 32.2330 | 0.9784          | 3.4922          | 0.2154 |
| CE      | 0.7551         | 0.0090                              | 0.9688         | 7.4297                                     | 14.7730 | 0.9832          | 6.8865          | 0.3980 |


- ✓ **CE formulation presented a higher value of K<sub>H</sub>** which indicated the complex formation and the enhancement of drug dissolution compared to other formulations.
- ✓ The **exponent (n)** of the Korsmeyer–Peppas model indicated that the drug release is related to a quasi-Fickian diffusion (n < 0.5).




# Results and discussion – *Preparation of ternary inclusion complexes (TIC)*



Binary inclusion complex (BIC)




Polyvinylpyrrolidone (PVP)



Ternary inclusion complex (TIC)

✓ Each binary system was co-milled at ambient temperature in presence of different ratios of a highly water-soluble polymer (PVP).




## Results and discussion – *In vitro* release of MA from ternary inclusion complexes

| % of PVP          | 2%      |         |         | 5%     |        |        | 10%     |         |        |
|-------------------|---------|---------|---------|--------|--------|--------|---------|---------|--------|
| TIC               | F1(PM)  | F2(KN)  | F3(CE)  | F4(PM) | F5(KN) | F6(CE) | F7(PM)  | F8(KN)  | F9(CE) |
| Time              | 120 min | 120 min | 120 min | 90 min | 30 min | 20 min | 120 min | 120 min | 90 min |
| % of drug release | 50      | 90      | 99      | 100    | 100    | 100    | 60      | 92      | 99     |

- ✓ The **CE method** is the most appropriate method to get improved MA dissolution properties of (2:1) MA:β-CD binary complex.
- ✓ The **add of 5% of PVP** to the CE binary system (F6), the dissolution of MA was significantly improved. This ternary inclusion complex constitutes the best dosage form.




## Results and discussion – *In vivo* evaluation



- ✓ To assess the *in vivo* anti-inflammatory effectiveness of the formulations (CE and F6) in comparison with the pure drug, Carrageenan-induced rat paw edema test was used.
- ✓ The strongest inhibitory effect on the total edema response was observed for F6.

- ✓ Acetic acid-induced writhing test was used to evaluate the analgesic activity of the formulations (CE and F6) in comparison with the pure drug.
- ✓ The treatment with ternary inclusion complex (F6) by oral administration remove writhing and enhancing the anti-nociceptive effect.



## Conclusions

- ✓ **Phase solubility diagram** and **job's plot experiment** were used to determine the stoichiometry of the MA: $\beta$ -CD complex. Molecular modeling approach helps to select the most stable inclusion complex (2:1).
- ✓ **Inclusion complexes of MA: $\beta$ -CD** in the 2:1 molar ratio were prepared using PM, KN and CE methods.
- ✓ **Characterization of BIC** showed no evidence of chemical reactions between MA and  $\beta$ -CD.
- ✓ **Add of 5% of PVP** to the CE binary inclusion complex exhibited the highest enhancement in MA dissolution properties.
- ✓ **Ternary inclusion complex** (F6) constitutes the best dosage form. In vivo anti-inflammatory and analgesic assays confirmed the therapeutic benefits of MA when its solubility is improved.



## Acknowledgments

The authors are very grateful to “Ministère de l’Enseignement Supérieur et de la Recherche Scientifique de l’Algérie” as well as University of Ferhat Abbas Sétif 1 for the funding and the support of the project.

Our thanks go to SALEM Pharmaceutical Laboratories headed by Dr. A. Maiza for the supply of the different chemicals used in this study.

Pr. M. Boutahala is gratefully acknowledged for the provision of the equipments used in the analyses as well as the laboratory facilities.

